Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Inclusion Criteria

• •Platelet count \>= 100,000/mm\^3
• •Histologically or cytologically confirmed non-small cell lung cancer meeting 1 of the following criteria:
• •* Stage IV disease
• •* Stage IIIB disease with pleural effusion
• •* Recurrent disease after surgery or radiotherapy
• •Measurable disease, defined as \>= 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan
• •Previously treated brain metastasis allowed, provided there is no bleeding, no midline shift, no need for steroids or anti-convulsants, and no symptoms
• •Must agree to obtain residual tumor tissue available from the existing diagnostic biopsy tumor tissue
• •Eastern cooperative oncology group (ECOG) performance status (PS) 0-1 OR Karnofsky PS 60-100%
• •Life expectancy \> 12 weeks
• •White blood cell (WBC) \>= 3,000/mm\^3
• •Absolute neutrophil count \>= 1,500/mm\^3
• •Bilirubin =\< 1.5 times upper limit of normal (ULN)
• •Aspartate aminotransferase (AST) and ALT =\< 2.5 times ULN
• •Creatinine =\< 3 times ULN OR Creatinine clearance \>= 60 mL/min
• •No uncontrolled congestive heart failure or potentially life-threatening arrhythmia
• •No angina at rest
• •No neuropathy \>= grade 2
• •No chronic diarrhea or history of inflammatory bowel disease
• •No history of pulmonary fibrosis (other than in an irradiated field)
• •No other concurrent serious medical illness
• •O2 saturation \> 92% on room air
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No history of allergic reactions to compounds of similar chemical or biological composition to dasatinib
• •No heart rate-corrected QT interval (QTc) prolongation (i.e., QTC \>= 480 msec) or other significant ECG abnormalities that could lead to adverse effects if the QTc interval were prolonged
• •No medical condition that impairs the ability to swallow, retain, or absorb dasatinib including, but not limited to, any of the following:
• •* Gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease
• •No myocardial infarction or ventricular tachyarrhythmia within the past 6 months
• •left ventricular ejection fraction (LVEF) normal
• •No major conduction abnormality (unless cardiac pacemaker is present)
• •No ongoing or active infection
• •No history of significant bleeding disorder (congenital \[von Willebrand's disease\] or acquired \[antifactor VIII antibodies\])
• •No psychiatric illness or social situation that would preclude study compliance
• •No prior chemotherapy or biologic therapy for recurrent or metastatic non-small cell lung cancer
• •Adjuvant cytotoxic chemotherapy after surgical resection or chemotherapy with radiation for locally advanced disease (curative intent) allowed provided disease recurrence \>= 3 months after completion of last chemotherapy dose
• •Measurable disease must be outside the radiotherapy port OR clearly growing inside the port
• •No prior radiotherapy to \>= 25% of the marrow-containing skeleton
• •At least 7 days since prior and no concurrent medications that are inhibitors or inducers of CYP3A4
• •At least 7 days since prior and no concurrent agents with proarrhythmic potential
• •No other concurrent investigational agents
• •No other concurrent anticancer agents or therapies
• •No concurrent antiretroviral therapy for HIV-positive patients
• •No concurrent systemic antacids (H2 receptor antagonists and proton pump inhibitors)
• •Locally acting antacids allowed except for 2 hours before and after dasatinib administration